GPCR dynamics, shown in purple as the human A 2A receptor, and elegant modifications in activation pathways (allostery) indicated by the blue arrow, are critical for enabling GPCRs to bind to multiple ...

Artificial intelligence is accelerating breakthroughs in G protein-coupled receptor (GPCR) research, a key area for developing new medicines. From predicting complex receptor structures to screening ...

Drug discovery can be a long and complex process. Medicines for neurodegenerative diseases like Alzheimer's disease are among the most expensive to develop, as animal model results have not proven to ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has revealed how a tryptophan-rich allosteric communication network regulates ...

Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule ...

GPCRs are the largest receptor class, affecting almost every aspect of human physiology, with 35% of all approved drugs acting on GPCRs. They regulate sensory and neuronal signaling, as well as a ...

Computational analysis using rigidity-theory indicates that activation of the human adenosine A 2A receptor (shown here) is regulated by long-range allosteric communication pathways (highlighted in ...

Researchers have discovered how unstructured segments of surface proteins regulate the biological function of a cell. Their study, published in Nature Communications, sheds new light on the interplay ...

Most protein-targeting drugs are prizes that drug developers have unearthed from G protein–coupled receptor (GPCR) interactomes. So, when GPCR-targeting drugs become harder to find, one might liken ...

Septerna just entered the clinic, and its lack of human data makes it an outlier among the companies able to successfully go public this year in what is still a cautious biotech IPO market. What the ...